Heidelberg Pharma AG Stock
Price
Target price
€3.09
€3.09
-2.250%
-0.07
-2.250%
-
13.11.25 / Tradegate
WKN: A11QVV / Name: Heidelberg Pharma / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Heidelberg Pharma AG Stock
A loss of -2.250% shows a downward development for Heidelberg Pharma AG.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Heidelberg Pharma AG stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Heidelberg Pharma AG in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Heidelberg Pharma AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Heidelberg Pharma AG | -2.250% | -0.643% | 0.000% | 26.639% | 30.380% | -49.178% | -27.465% |
| Nanorepro AG | -4.660% | -1.548% | -4.505% | 6.000% | 20.000% | -38.012% | -55.085% |
| Vivoryon Therapeutics N.V. | 0.490% | 0.988% | -1.918% | -21.346% | -18.118% | -81.021% | -67.280% |
| Vaxart Inc. | -2.140% | -5.822% | 4.246% | -57.951% | -59.199% | -81.829% | -93.664% |
Comments
systinvest bought the security Heidelberg Pharma AG in his wikifolio Aktienwertselektion mit System.
Show more
News
EQS-News: Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
EQS-News: Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
EQS-News: Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar
EQS-News: Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar
EQS-News: Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
EQS-News: Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma